Relationship between exhaled leukotriene and 8-isoprostane levels and asthma severity, asthma control level, and asthma control test score

Keskin, Özlem; Balaban, Sinan; Keskın, Mehmet; Kucukosmanoglu, Ercan; Göğebakan, Bülent; Özkars, Mehmet Yaşar; Kül, Seval; Bayram, Hasan; Coşkun, Yavuz

doi:10.1016/j.aller.2012.09.003

Cited by 12 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exhaled breath condensate (EBC) is a non-invasive test which measures airway inflammation by the collection of airway secretions [ 31 ]. The condensate contains unstable volatile (H2O2) and semi- and non-volatile molecules (proteins and cytokines) carried by respiratory droplets.…”

Section: Biomarkersmentioning

confidence: 99%

The Predictive Role of Biomarkers and Genetics in Childhood Asthma Exacerbations

Palmo

Cantarelli

Catelli

et al. 2021

IJMS

View full text Add to dashboard Cite

Asthma exacerbations are associated with significant childhood morbidity and mortality. Recurrent asthma attacks contribute to progressive loss of lung function and can sometimes be fatal or near-fatal, even in mild asthma. Exacerbation prevention becomes a primary target in the management of all asthmatic patients. Our work reviews current advances on exacerbation predictive factors, focusing on the role of non-invasive biomarkers and genetics in order to identify subjects at higher risk of asthma attacks. Easy-to-perform tests are necessary in children; therefore, interest has increased on samples like exhaled breath condensate, urine and saliva. The variability of biomarker levels suggests the use of seriate measurements and composite markers. Genetic predisposition to childhood asthma onset has been largely investigated. Recent studies highlighted the influence of single nucleotide polymorphisms even on exacerbation susceptibility, through involvement of both intrinsic mechanisms and gene-environment interaction. The role of molecular and genetic aspects in exacerbation prediction supports an individual-shaped approach, in which follow-up planning and therapy optimization take into account not only the severity degree, but also the risk of recurrent exacerbations. Further efforts should be made to improve and validate the application of biomarkers and genomics in clinical settings.

show abstract

Section: Biomarkersmentioning

confidence: 99%

The Predictive Role of Biomarkers and Genetics in Childhood Asthma Exacerbations

Palmo

Cantarelli

Catelli

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Low EBC pH may be a potential biomarker to identify asthma patients and exacerbations of asthma, but its clinical utility is controversial (55). 8-isoprostane levels are also higher in children with asthma (56) and may be increased as a function of exacerbations and asthma severity (57). Similarly, EBC hydrogen peroxide (H 2 O 2 ) concentrations are increased in children with asthma exacerbations and remain elevated despite treatment (58).…”

Section: Diagnostics and Biomarkersmentioning

confidence: 99%

Asthma across the ages: Knowledge gaps in childhood asthma

Szefler

Chmiel

Fitzpatrick

et al. 2014

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

The Eunice Kennedy Shriver National Institute of Child Health and Human Development convened an Asthma Group in response to the Best Pharmaceuticals for Children Act (BPCA). The overall goal of the BPCA Program is to improve pediatric therapeutics through preclinical and clinical drug trials that lead to drug labeling changes. While significant advances have been made in the understanding and management of asthma in adults with appropriately labeled medications, less information is available on the management of asthma in children. Indeed, many medications are inadequately labeled in children. In general, the younger the child, the less information there is available to guide clinicians. Since asthma often begins in early childhood, it is incumbent upon us to continue to address the primary questions raised in this review and carefully evaluate medications used to manage asthma in children. Meanwhile, continued efforts should be made in defining effective strategies that reduce the risk of exacerbations. If the areas of defined need are addressed in the coming years, namely prevention of exacerbations and progression of disease, as well as primary intervention, we will see continuing reduction in asthma mortality and morbidity along with improved quality of life for children with asthma.

show abstract

“…8-isoprostane (8-IP) is increased in childhood asthma, and then particularly in children with severe asthma or with an asthma exacerbation (6). This finding was replicated in a small study in which 8-IP levels were higher in moderate persistent asthma compared to mild persistent asthma (16). Moreover, 8-IP levels in this study were higher in children having >4 exacerbations per year compared to children with 1–4 exacerbations per year (16).…”

Section: Findings From Cross-sectional Studiesmentioning

confidence: 59%

“…In the same study, cysteinyl leukotrienes (Cys-LTs) in EBC showed a tendency to increased levels in the moderate persistent asthma group, but not a significant difference (16). Both the lower detection rate (73%) and the low sample size could be potential causes for this lack of significance.…”

Section: Findings From Cross-sectional Studiesmentioning

confidence: 83%

“…Another interesting finding from our review is the shift to study specific subgroups in childhood asthma, including preschool wheezing (32, 33), children with asthma and EIB symptoms (19, 24, 25, 35), mild vs. severe asthma (12–14, 16), controlled vs. uncontrolled asthma (16, 21, 37), and asthma exacerbations (29–31, 36). Most studies focused on the diagnostic potential to differentiate between two well-defined groups at a certain time-point (cross-sectional study design).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exhaled Breath Condensate in Childhood Asthma: A Review and Current Perspective

2019

View full text Add to dashboard Cite

Exhaled breath condensate (EBC) was introduced more than two decades ago as a novel, non-invasive tool to assess airway inflammation. This review summarizes the latest literature on the various markers in EBC to predict asthma in children. Despite many recommendations and two comprehensive Task Force reports, there is still large heterogeneity in published data. The biggest issue remains a lack of standardization regarding EBC collection, preservation, processing, and analysis. As a result, published studies show mixed or conflicting results, questioning the reproducibility of findings. A joint, multicenter research study is urgently needed to address the necessary methodological standardization.

show abstract

Relationship between exhaled leukotriene and 8-isoprostane levels and asthma severity, asthma control level, and asthma control test score

Cited by 12 publications

References 29 publications

The Predictive Role of Biomarkers and Genetics in Childhood Asthma Exacerbations

The Predictive Role of Biomarkers and Genetics in Childhood Asthma Exacerbations

Asthma across the ages: Knowledge gaps in childhood asthma

Exhaled Breath Condensate in Childhood Asthma: A Review and Current Perspective

Contact Info

Product

Resources

About